{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Fibrosis+and+Cirrhosis+of+Liver&page=3",
    "query": {
      "condition": "Fibrosis and Cirrhosis of Liver",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 553,
    "total_pages": 56,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Fibrosis+and+Cirrhosis+of+Liver&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Fibrosis+and+Cirrhosis+of+Liver&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-12T02:25:27.245Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03855956",
      "title": "Clinical Food Study to Evaluate the Effect of KB174 on the Gut Microbiome in Subjects With Well-compensated Cirrhosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Early Cirrhosis"
      ],
      "interventions": [
        {
          "name": "KB174",
          "type": "OTHER"
        },
        {
          "name": "Maltodextrin",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Kaleido Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 40,
      "start_date": "2019-02-27",
      "completion_date": "2019-10-01",
      "has_results": false,
      "last_update_posted_date": "2020-05-14",
      "last_synced_at": "2026-10-12T02:25:27.245Z",
      "location_count": 4,
      "location_summary": "Hollywood, Florida • Miami, Florida • Winter Park, Florida + 1 more",
      "locations": [
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Winter Park",
          "state": "Florida"
        },
        {
          "city": "Monroe",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03855956"
    },
    {
      "nct_id": "NCT00018031",
      "title": "Peginterferon Alpha-2b And Ribavirin to Treat Hepatitis C in HIV-Infected Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis C",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Peginterferon alfa-2b",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2001-06",
      "completion_date": "2009-04",
      "has_results": true,
      "last_update_posted_date": "2014-10-01",
      "last_synced_at": "2026-10-12T02:25:27.245Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00018031"
    },
    {
      "nct_id": "NCT01088607",
      "title": "Safety and Efficacy Study of Ursodeoxycholic Acid Therapy in Pediatric Primary Sclerosing Cholangitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Primary Sclerosing Cholangitis"
      ],
      "interventions": [
        {
          "name": "ursodeoxycholic acid (UDCA)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Tennessee",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "5 Years to 21 Years"
      },
      "enrollment_count": 27,
      "start_date": "2010-10",
      "completion_date": "2017-06",
      "has_results": false,
      "last_update_posted_date": "2017-10-26",
      "last_synced_at": "2026-10-12T02:25:27.245Z",
      "location_count": 12,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • San Francisco, California + 9 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01088607"
    },
    {
      "nct_id": "NCT01904409",
      "title": "Dose-ranging Study of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Prevention of Complications of Early Decompensated Liver Cirrhosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Liver Cirrhosis"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Rifaximin SSD 40 mg IR tablet",
          "type": "DRUG"
        },
        {
          "name": "Rifaximin SSD 80 mg IR tablet",
          "type": "DRUG"
        },
        {
          "name": "Rifaximin SSD 40 mg SER tablet",
          "type": "DRUG"
        },
        {
          "name": "Rifaximin SSD 80 mg SER tablet",
          "type": "DRUG"
        },
        {
          "name": "Rifaximin SSD 80mgIR/80mgSER tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bausch Health Americas, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 420,
      "start_date": "2013-06",
      "completion_date": "2015-07",
      "has_results": false,
      "last_update_posted_date": "2019-10-23",
      "last_synced_at": "2026-10-12T02:25:27.245Z",
      "location_count": 113,
      "location_summary": "Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 94 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Artesia",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01904409"
    },
    {
      "nct_id": "NCT03486899",
      "title": "A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Liver Fibrosis",
        "Nonalcoholic Fatty Liver Disease (NAFLD)",
        "Nonalcoholic Steatohepatitis"
      ],
      "interventions": [
        {
          "name": "BMS-986036",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 197,
      "start_date": "2018-06-19",
      "completion_date": "2021-08-17",
      "has_results": true,
      "last_update_posted_date": "2022-09-09",
      "last_synced_at": "2026-10-12T02:25:27.245Z",
      "location_count": 83,
      "location_summary": "Madison, Alabama • Chandler, Arizona • Phoenix, Arizona + 61 more",
      "locations": [
        {
          "city": "Madison",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03486899"
    },
    {
      "nct_id": "NCT03684187",
      "title": "Mindfulness - Based Intervention in the Treatment of Fatigue in Patients With Primary Biliary Cholangitis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Primary Biliary Cholangitis"
      ],
      "interventions": [
        {
          "name": "Mindfulness Based Intervention",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 6,
      "start_date": "2018-11-19",
      "completion_date": "2023-04-17",
      "has_results": false,
      "last_update_posted_date": "2025-05-25",
      "last_synced_at": "2026-10-12T02:25:27.245Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03684187"
    },
    {
      "nct_id": "NCT05692024",
      "title": "COffee and Metabolites Modulating the Gut MicrobiomE in Colorectal caNCER",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Cancer",
        "Coffee",
        "Gastrointestinal Microbiome",
        "Stenosis",
        "Fibrosis, Liver",
        "Ultrasound Elastography",
        "Proton Magnetic Resonance Spectroscopy"
      ],
      "interventions": [
        {
          "name": "Nestlé NESCAFÉ® TASTER'S CHOICE® House Blend capsule.",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 80,
      "start_date": "2024-03-21",
      "completion_date": "2028-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-05",
      "last_synced_at": "2026-10-12T02:25:27.245Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05692024"
    },
    {
      "nct_id": "NCT02774161",
      "title": "B-mode Ultrasound Imaging in Detecting Early Liver Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cirrhosis",
        "Early Hepatocellular Carcinoma",
        "Fibrosis",
        "Stage I Hepatocellular Carcinoma",
        "Stage II Hepatocellular Carcinoma"
      ],
      "interventions": [
        {
          "name": "Ultrasound Tomography",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2016-05",
      "completion_date": "2017-06-19",
      "has_results": false,
      "last_update_posted_date": "2021-08-03",
      "last_synced_at": "2026-10-12T02:25:27.245Z",
      "location_count": 1,
      "location_summary": "Palo Alto, California",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02774161"
    },
    {
      "nct_id": "NCT02230670",
      "title": "A Study of IDN-6556 in Subjects With Liver Cirrhosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Liver Cirrhosis",
        "Hepatic Cirrhosis"
      ],
      "interventions": [
        {
          "name": "IDN-6556",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Conatus Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 87,
      "start_date": "2014-08",
      "completion_date": "2016-01",
      "has_results": true,
      "last_update_posted_date": "2017-07-05",
      "last_synced_at": "2026-10-12T02:25:27.245Z",
      "location_count": 28,
      "location_summary": "Birmingham, Alabama • La Jolla, California • Loma Linda, California + 21 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02230670"
    },
    {
      "nct_id": "NCT01831037",
      "title": "The Regression of Liver Fibrosis and Risk for Hepatocellular Carcinoma (ROLFH) Study",
      "overall_status": "WITHDRAWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Chronic Hepatitis C",
        "Chronic Hepatitis B"
      ],
      "interventions": [
        {
          "name": "Regression of fibrosis",
          "type": "OTHER"
        },
        {
          "name": "Specific risk factors related to hepatocellular carcinoma",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Arkansas",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 0,
      "start_date": "2015-07",
      "completion_date": "2019-12",
      "has_results": false,
      "last_update_posted_date": "2015-01-28",
      "last_synced_at": "2026-10-12T02:25:27.245Z",
      "location_count": 2,
      "location_summary": "Little Rock, Arkansas • Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01831037"
    }
  ]
}